Anti-Lysophosphatidic Acid Receptor (Edg4, LPA2)

LPAR2 is a 39kD member of the GPCR1 family of proteins. It has limited expression, and is found on mammalian macrophages, fibroblasts and cardiac myocytes. LPAR2 binds to, and is activated by LPA, a molecule principally derived from activated platelets. Although LPAR2 appears to prefer myristoyl and palmitoyl LPA, multiple forms of LPA are recognized by the receptor. LPAR2 reportedly mediates chemotaxis, arachidonic acid release, and cell rounding. Human LPAR2 is a 351aa 7-transmembrane (TM) protein (SwissProt #Q9HBW0). It contains a 33aa extracellular N-terminus aa#1-33, seven TM segments aa#34-297 and a 54aa C-terminal cytoplasmic tail. There is one splice variant that is associated with tumor cells, and which originally was given the designation EDG4 (endothelium differentiation gene 4). This shows a 35aa substitution for aa#348-351. Over aa#1-33, 91-103, 168-188 and 264-279 collectively, human LPAR2 shares 75aa identity with mouse LPAR2. Applications: Suitable for use in Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 1ug/ml, Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.